|
CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
|
EP0954574A2
(en)
*
|
1996-07-01 |
1999-11-10 |
Jim A. Wright |
Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
|
|
US6593305B1
(en)
|
1996-08-02 |
2003-07-15 |
Genesense Technologies Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
WO1998041231A1
(en)
*
|
1997-03-19 |
1998-09-24 |
Genesense Technologies, Inc. |
Suppression of malignancy utilizing ribonucleotide reductase r1
|
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
|
US6610539B1
(en)
*
|
1997-07-10 |
2003-08-26 |
Genesense Technologies, Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
EP1584681A3
(en)
*
|
1997-07-10 |
2005-11-09 |
GeneSense Technologies Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
US6506559B1
(en)
*
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AUPP249298A0
(en)
*
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
ES2374534T3
(es)
*
|
1998-03-20 |
2012-02-17 |
Commonwealth Scientific And Industrial Research Organisation |
Control de la expresión de genes.
|
|
EP2314700A1
(en)
*
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
|
US6121000A
(en)
*
|
1999-02-11 |
2000-09-19 |
Genesense Technologies, Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
|
US6642033B1
(en)
*
|
1999-07-20 |
2003-11-04 |
V.I. Technologies, Inc. |
Nucleic acids for detecting parvovirus and methods of using same
|
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
|
CN1301816A
(zh)
*
|
1999-12-27 |
2001-07-04 |
上海博德基因开发有限公司 |
一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
|
|
CN1426466A
(zh)
*
|
2000-03-17 |
2003-06-25 |
贝尼泰克澳大利亚有限公司 |
遗传沉默
|
|
EP1229134A3
(en)
*
|
2001-01-31 |
2004-01-28 |
Nucleonics, Inc |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
|
DE10131148A1
(de)
*
|
2001-06-28 |
2003-01-16 |
I P L Internat Pharmaceutics L |
Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
|
|
AU2004209579B2
(en)
*
|
2003-02-10 |
2010-03-04 |
Lorus Therapeutics Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer
|
|
WO2004083432A1
(en)
*
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
EP1636363A1
(en)
*
|
2003-05-21 |
2006-03-22 |
GeneSense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
|
|
WO2004106518A1
(en)
*
|
2003-05-31 |
2004-12-09 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
|
CN1910293B
(zh)
|
2003-10-23 |
2011-04-13 |
伊洛默格生物科学公司 |
检测与抗病毒感染性有关的基因oas1中的突变的方法
|
|
WO2005065719A1
(en)
*
|
2004-01-12 |
2005-07-21 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
|
|
EP1744761A4
(en)
*
|
2004-04-28 |
2010-01-13 |
Molecules For Health Inc |
METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER
|
|
EP2322650A1
(en)
*
|
2004-05-14 |
2011-05-18 |
Rosetta Genomics Ltd |
MicroRNAs and uses thereof
|
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
|
EP1786905B1
(en)
*
|
2004-08-18 |
2011-08-03 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
US20060185027A1
(en)
*
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
|
CA2603730A1
(en)
*
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
EP2030615A3
(en)
*
|
2007-08-13 |
2009-12-02 |
ELFORD, Howard L. |
Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
|
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
PE20091523A1
(es)
|
2007-12-20 |
2009-10-29 |
Novartis Ag |
Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
|
|
WO2010027279A2
(en)
*
|
2008-09-04 |
2010-03-11 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
|
EP2727996A1
(en)
|
2008-11-06 |
2014-05-07 |
The Johns-Hopkins University |
Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
WO2012052258A1
(en)
*
|
2010-10-18 |
2012-04-26 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting expression of rrm2 genes
|
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
|
KR20140090218A
(ko)
|
2011-10-28 |
2014-07-16 |
노파르티스 아게 |
신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
|
|
WO2013173283A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
CA2930359C
(en)
|
2013-12-06 |
2022-03-01 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|